



## CHILTERN LAUNCHES COLLABORATIVE TECHNOLOGIES

**London, UK, June 10, 2010:** Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced the launch of **Collaborative Technologies**.

"Chiltern's Collaborative Technologies is a turnkey solution reflecting integrated processes and technology which offers a single access point to clinical study data and the central document repository for the entire study team. Our Data Warehousing brings together data from core clinical systems to present one consolidated view of information," stated **Dr Jim Esinhart**, Chiltern Executive Vice President, Global Biometrics and North America.

**Glenn Kerkhof**, Chiltern CEO, commented, "A key benefit of Collaborative Technologies is the immediate access to current study information which the entire study team can access wherever they are located globally. This means faster decisions can be made on the study which results in time and cost savings for our clients."

Dr Esinhart added, "In addition to the core components in the Collaborative Technologies platform, it has been configured to work with Chiltern's proprietary systems such as **Chiltern Insight**, our clinical trial management system, and **Chiltern Safe**, our Trial Master File and Electronic Records Management system. We are extremely pleased to report that Collaborative Technologies works hand-in-hand with our industry's leading systems such as Medidata Rave® and Clinphone Datalabs® for Electronic Data Capture (EDC), Phase Forward's Empirica™ Trace for adverse event management and **endpoint's PULSE** for Interactive Response Technology (IRT). To summarize, Collaborative Technologies offers our clients a suite of best-in-class technological solutions for their clinical trial needs under one organization."

### Company profile

#### About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 20 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: [www.chiltern.com](http://www.chiltern.com).

#### Contact:

Natalie Chong, Marketing Director  
Chiltern International Ltd.  
171 Bath Road  
Slough  
Berkshire SL1 4AA  
UNITED KINGDOM  
Tel: +44 (0) 1753 512 000  
Fax: +44 (0) 1753 511 116  
[natalie.chong@chiltern.com](mailto:natalie.chong@chiltern.com)

Susan Ojanen, Marketing Associate  
Chiltern International Inc.  
1241 Volunteer Parkway  
Suite 950  
Bristol, TN 37620  
USA  
Tel: +1 (423) 968 9533  
Fax: +1 (423) 968 3567  
[susan.ojanen@chiltern.com](mailto:susan.ojanen@chiltern.com)